LIVE WEBINAR: Tuesday, February 13, 2024 | 5:00 PM – 6:00 PM Eastern Time (ET)

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Oncology

A Multitumor CME/MOC-Accredited Live Webinar Series


Join us on Tuesday, February 13th for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

Andrew M Evens, DO, MBA, MSc
Deputy Director for Clinical Services
Rutgers Cancer Institute of New Jersey
Associate Vice Chancellor, Clinical Innovation
and Data Analytics
Rutgers Health
System Director of Medical Oncology and Oncology Lead for RWJBarnabas-Rutgers Medical Group
RWJBarnabas Health
Professor of Medicine, Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey

Sonali M Smith, MD
Elwood V Jensen Professor of Medicine
Chief, Section of Hematology/Oncology
Co-Leader, Cancer Service Line
Co-Director, Lymphoma Program
The University of Chicago
Chicago, Illinois

Neil Love, MD
Research To Practice
Miami, Florida

This activity is supported by educational grants from ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Incyte Corporation, and Seagen Inc.

Tuesday, February 13, 2024
5:00 PM – 6:00 PM ET
Live CME/MOC-accredited webinar

Topics to Be Discussed

  • PART I: Follicular and Mantle Cell Lymphoma
  • PART II: Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma

Target Audience
This program is intended for medical oncologists, hematology-oncology fellows, surgeons and other allied healthcare professionals involved in the treatment of lymphoma.

Learning Objectives
At the conclusion of this activity, participants should be able to

  • Recognize the mechanisms of action, efficacy and safety of approved and investigational agents for the treatment of diffuse large B-cell lymphoma (DLBCL) to determine the current and potential utility of those agents in clinical practice.
  • Incorporate available and emerging therapeutic strategies into the best-practice management of newly diagnosed and relapsed/refractory (R/R) Hodgkin lymphoma (HL).
  • Understand published research data informing the selection, sequencing or combining of available therapeutic agents in the nonresearch care of patients with previously untreated or R/R follicular lymphoma (FL).
  • Consider patient age, performance status and other clinical and biological factors in the up-front and subsequent treatment of mantle cell lymphoma (MCL).
  • Assess available clinical trial findings informing the use of CD19-directed chimeric antigen receptor T-cell therapy for R/R DLBCL, FL and MCL, and counsel appropriately selected patients regarding the potential benefits of this therapeutic strategy.
  • Evaluate the mechanism of action of and available clinical trial findings with bispecific antibodies targeting CD20 x CD3 in patients with FL and DLBCL, and determine the role of these agents in current clinical management.
  • Recall new data with agents and strategies currently under investigation for various lymphoma subtypes, and discuss ongoing trial opportunities with eligible patients.

CE Credit
CME and ABIM MOC credit links will be emailed to each participant within 3 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr EvensAdvisory Committees and Consulting Agreements: Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Incyte Corporation, Pfizer Inc; Data and Safety Monitoring Boards/Committees: Novartis, Pharmacyclics LLC, an AbbVie Company. Dr SmithConsulting Agreements: Bristol Myers Squibb, Gilead Sciences Inc, MorphoSys; Contracted Research: Acerta Pharma — A member of the AstraZeneca Group, Bristol Myers Squibb, Celgene Corporation, Curis Inc, Epizyme Inc, Forty Seven Inc, Genentech, a member of the Roche Group, Karyopharm Therapeutics, Pharmacyclics LLC, an AbbVie Company, Portola Pharmaceuticals Inc, TG Therapeutics Inc; Nonrelevant Financial Relationship: Spouse is employed at Caris Life Sciences.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI Biopharma, a Sobi company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Incyte Corporation, and Seagen Inc.